Now published in CGH : American Gastroenterological Association (AGA) Clinical Practice Update on Management of #IBD in Patients with #Malignancy

authors.elsevier.com/c/1j5Hd5UiFSkl…

Immense thanks to Jana G Hashash, MD, MSc and #StevenItzkowitz for helping to pull this together!

In IBD, and in medicine in general, it is increasingly important to identify those actions that do not add value (and can harm) and concentrate our efforts on what benefits our patients. Let's avoid “too much medicine”
cghjournal.org/article/S1542-…

#GUTImages from the #RecentAdvancesInClinicalPractice paper by Florian Rieder et al entitled

'Fibrosis in IBD: from pathogenesis to therapeutic targets' via bit.ly/4aLgTpO

Cleveland Clinic MD Pranab Mukherjee #Fibrosis #IBD

JAK inhibitors in IBD 👇🏿Frontline Gastro

✅ fg.bmj.com/content/15/1/59

Microbiota therapeutics for inflammatory bowel disease: the way forwar... sciencedirect.com/science/articl…

Here we go …

March is #ColonCancerAwarenessMonth and here at Inova Inova Schar Cancer Institute , we're committed to spreading awareness about the importance of screening. Our dedicated team is here to provide life-saving #colonoscopies for the people of Northern Virginia and the DC Capital Region 💙

1/3 Our top 3 abstracts for #ECCO24 for ibdupdate.ca Jeffrey McCurdy MD PhD Neeraj Narula
Reena Khanna Cynthia Seow #talatbessissow
#MondayNightIBD CAG IBD Horizons
#1 VIVID 1 Miri is effective in CD. Miri not superior to Ust. Are all IL-23's the same? Vipul Jairath MBChB DPhil

One of the most important #IBD studies this year!

Sequence data presented by Marla Dubinsky.

Risankizumab superior to Ustekinumab in Crohn’s (in prior Anti-TNF exposed).

Difficult decisions for budget holders with Ustekinumab going biosimilar in 2024.

#ECCO24

#ECCO24
Dr Zuzana Sercova with results of ADMIRE CD using MSCs in Perianal fistula
Didn’t meet both primary or secondary end points

🤔Back to drawing board

Impressive start of #ECCO24 by #NuruNoor presenting results from #PROFILE .
Paradigm-changing re the use of top-down in #IBD ?
👉🏼Severe endoscopic activity -> higher response
👉🏼No pts with mild CD included
👉🏼 Biomarker neg
Y-ECCO Gianluca Pellino Florian Rieder Edward Loftus

The PROFILE Crohn's Trial Study, as Dr. Jean-Frederic Colombel noted, did not cover pts w/ mild CD, & aggressive top-down therapy in mild CD is debatable #ECCO2024

🔥This is the best time to review Evidence-based strategies in the new issue of CGH #CGH4ALL

🔗doi.org/10.1016/j.cgh.…

78 #IBD pregnancies. 👶🏼ustekinumab clearance = 6 months ➡️ live 💉from 6 months of life is low risk. ⬇️risk of 👶🏼infections and normal development at 12 months.🇩🇰🇳🇱OPEN ACCESS cghjournal.org/article/S1542-… Gastroenterology CGH Department of Hepatology and Gastroenterology, AUH Crohn & Colitis - Erasmus MC Aarhus Uni.hospital HealthAU PREDICT IBD

Merry Christmas from IBDJournal & CC360! Thank you to our social media team for all of their work and Tweets during 2023! Ben Click Maia Kayal MD Shivi S Siva M.D. aka Shivi S. Sivanantham Damie Odufalu Neilanjan Nandi, MD, FACP Jean Donet

Congratulations to our colleagues in India, who got this RCT done in ASUC. Which JAKi is on formulary in your hospital? journals.lww.com/ajg/abstract/9…

Mirikizumab, an anti-IL-23p19 antibody, significantly improved all aspects of quality of life (physical & mental well-being 🙂, work productivity 💻) in patients with mod-severe UC. Bruce E. Sands Millie Long Vipul Jairath MBChB DPhil bit.ly/41yBwCj

#AIBD2023 @IBDConference #DrMarlaDubinsky

Which #EIMs in #IBD respond to #UST ? Which ones don’t ?

📸👇🏽 by systems

✅Joint
✅Derm
✅Uveitis
✅Aphthous mouth ulcers

Warming up at the DC airport with tacos and micheladas while reviewing the @IBDConference agenda! – best way to prepare

Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis:... sciencedirect.com/science/articl…

What a beautiful night for the Alexandria Holiday Boat Parade of Lights sponsored by Amazon! Here are some highlights: #ALXBoatParade